Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter ending June 30, 2026.

The Company expects total revenue of approximately $2.8 million for the second quarter of 2026, representing an approximate 21% increase compared to $2.3 million for the second quarter of 2025. For the six months ending June 30, 2026, the Company expects total revenue of approximately $5.0 million, representing an increase of 9% compared to $4.5 million for the same period in 2025.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.